Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judit Demeter

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
British Journal of Haematology|August 16, 2005
Genotype-phenotype correlation in MYH9-related thrombocytopeniaFan Dong, Sufeng Li, Núria Pujol-Moix, et al.
European Journal of Haematology|June 20, 2020
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirinAdam Kellner, Peter Dombi, Arpad Illes, et al.
Mycoses|February 3, 2017
Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope RegistryLuisa Durán Graeff, Danila Seidel, Maria J G T Vehreschild, et al.
Pathology Oncology Research : POR|February 4, 2019
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient ProgramGergely Varga, Zsolt Nagy, Judit Demeter, et al.
Journal of Neuro-Oncology|October 3, 2009
Central nervous system involvement in CD4+/CD56+ hematodermic neoplasm: a report of two casesNóra Eros, Márta Marschalkó, Katalin Balassa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2005
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapyAndrés J M Ferreri, Maurilio Ponzoni, Massimo Guidoboni, et al.
Pathology|January 5, 2019
Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasmsRéka Mózes, Ambrus Gángó, Adrienn Sulák, et al.
Annals of Hematology|April 22, 2020
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphomaAndrew Davies, Peter Trask, Judit Demeter, et al.
Pathology Oncology Research : POR|April 23, 2017
Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)Tamás Schneider, András Rosta, Hajna Losonczy, et al.
Haematologica|September 28, 2023
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II studyChristopher R Flowers, Matthew J Matasar, Alex F Herrera, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|August 16, 2005
Genotype-phenotype correlation in MYH9-related thrombocytopeniaFan Dong, Sufeng Li, Núria Pujol-Moix, et al.
European Journal of Haematology|June 20, 2020
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirinAdam Kellner, Peter Dombi, Arpad Illes, et al.
Mycoses|February 3, 2017
Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope RegistryLuisa Durán Graeff, Danila Seidel, Maria J G T Vehreschild, et al.
Pathology Oncology Research : POR|February 4, 2019
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient ProgramGergely Varga, Zsolt Nagy, Judit Demeter, et al.
Journal of Neuro-Oncology|October 3, 2009
Central nervous system involvement in CD4+/CD56+ hematodermic neoplasm: a report of two casesNóra Eros, Márta Marschalkó, Katalin Balassa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2005
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapyAndrés J M Ferreri, Maurilio Ponzoni, Massimo Guidoboni, et al.
Pathology|January 5, 2019
Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasmsRéka Mózes, Ambrus Gángó, Adrienn Sulák, et al.
Annals of Hematology|April 22, 2020
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphomaAndrew Davies, Peter Trask, Judit Demeter, et al.
Pathology Oncology Research : POR|April 23, 2017
Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)Tamás Schneider, András Rosta, Hajna Losonczy, et al.
Haematologica|September 28, 2023
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II studyChristopher R Flowers, Matthew J Matasar, Alex F Herrera, et al.
Pageof 9